EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer

Wei Du, Bijing Xiao, Xuan Yang, Jianhua Zhan, Haishuang Sun, Yunpeng Yang, Wenfeng Fang, Yan Huang, Dongchen Sun, Shaodong Hong, Li Zhang

Cancer Immunology, Immunotherapy · 13.09.2025 · 74 (10)

DOI: 10.1007/s00262-025-04165-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 13.09.2025. Verfasst von Wei Du und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Tertiary Lymphoid Structures. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with chemoimmunotherapy (CIT) as the first-line standard for advanced NSCLC without driver mutations. However, predictive biomarkers for CIT response are limited. Tertiary lymphoid structures (TLS) play a critical role in antitumor immunity and may serve as potential biomarkers. This study aimed to screen and validate a TLS-derived gene signature to predict responses to first-line CIT in advanced NSCLC. METHODS: Data from three randomized trials (ORIENT-11, OAK, POPLAR) and The Cancer Genome Atlas-NSCLC were analyzed. TLS scores were computed via ssGSEA based on 17 TLS-related gene signatures. Patients were stratified into TLS-high and TLS-low groups. The predictive value was assessed by survival analysis, nomograms, and receiver operating characteristic curve. Correlations with programmed cell death 1 ligand (PD-L1) and ImmuneScore were evaluated. RESULTS: TLS signature 3 was identified as a predictive biomarker. In ORIENT-11, high signature 3 scores correlated with longer progression-free survival (PFS) (9.92 vs 6.77 months, p = 0.001) and overall survival (OS) (not reached vs 17.60 months, p < 0.001). Multivariate analysis confirmed signature 3 as an independent predictor for both outcomes (PFS HR = 2.14, p = 0.006; OS HR = 2.24, p = 0.002). A nomogram integrating signature 3 and clinicopathologic factors showed strong discriminative power. Signature 3 also correlated with PD-L1 expression and 'hot' immune phenotypes, enhancing prediction in PD-L1-negative subsets. CONCLUSIONS: TLS signature 3 predicts CIT response independently of PD-L1, improving outcomes in PD-L1-negative patients and complementing PD-L1 testing. Integration into clinical practice may refine treatment decisions, warranting further mechanistic and clinical validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyTertiary Lymphoid StructuresBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedPrognosisAgedB7-H1 Antigen

Stichwörter der Autor:innen

First-lineNon-small cell lung cancerPlatinum-based chemotherapy combined with immunotherapyTertiary lymphoid structures

Substanzen

Biomarkers, TumorB7-H1 Antigen

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, No. 651 DongFeng Road E, Guangzhou, 510060, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. sundc@sysucc.org.cn.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, No. 651 DongFeng Road E, Guangzhou, 510060, China. sundc@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. hongshd@sysucc.org.cn.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, No. 651 DongFeng Road E, Guangzhou, 510060, China. hongshd@sysucc.org.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • National Science and Technology Major Project
  • Guangzhou Municipal Science and Technology Project

Zitieren

APA

Du, W., Xiao, B., Yang, X., Zhan, J., Sun, H., Yang, Y., Fang, W., Huang, Y., Sun, D., Hong, S., & Zhang, L. (2025). Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer. Cancer Immunology, Immunotherapy, 74(10). https://doi.org/10.1007/s00262-025-04165-2

Vancouver

Du W, Xiao B, Yang X, Zhan J, Sun H, Yang Y, et al. Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2025;74(10). doi:10.1007/s00262-025-04165-2

BibTeX
@article{Du2025,
  author = {Du, Wei and Xiao, Bijing and Yang, Xuan and Zhan, Jianhua and Sun, Haishuang and Yang, Yunpeng and Fang, Wenfeng and Huang, Yan and Sun, Dongchen and Hong, Shaodong and Zhang, Li},
  title = {Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {10},
  doi = {10.1007/s00262-025-04165-2}
}
Kostenlos starten →